Gastric Cancer Clinical Trials

A listing of Gastric Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 47 clinical trials
Study to Assess the Safety Tolerability and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer

This is an open-label, Phase 1b study to evaluate the safety and tolerability of IDX-1197 and determine the MTD and RP2D in combination with XELOX or irinotecan in patients with advanced gastric

metastatic gastric cancer
measurable disease
irinotecan
cancer chemotherapy
xelox regimen
  • 0 views
  • 03 Sep, 2021
  • 12 locations
Chemotherapy Combined With Apatinib and PD-1 Antibody

The effective rate of second-line and later-line single-agent therapy for advanced gastric cancer is limited. This research plan aims to explore whether the combination of drugs can further

adjuvant chemotherapy
cancer chemotherapy
liver metastasis
immunostimulants
apatinib
  • 0 views
  • 03 Sep, 2021
  • 1 location
A Dose-escalation Expansion Study of ARX788 in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)

This 2-part, Phase 1, open-label study will determine the recommended Phase 2 dose (RP2D) of ARX788 in subjects with advanced HER2 positive cancers and will assess the safety and anticancer activity in breast, gastric and other advanced HER2 positive solid tumors.

esophageal cancer
mammogram
renal function
trastuzumab
renal function test
  • 16 views
  • 08 Sep, 2021
  • 9 locations
A First-in-human Study Using BDC-1001 in Advanced HER2-Expressing Solid Tumors

A first-in-human study using BDC-1001 in HER2 expressing advanced malignancies

measurable disease
advanced malignant solid tumor
pembrolizumab
erbb2
HER2
  • 23 views
  • 03 Sep, 2021
  • 21 locations
Safety Tolerability and Efficacy Profile of Rivoceranib With Paclitaxel in Advanced GC or GEJ Cancer.

This is an open-label, single-center, single-arm, dose escalation and dose expansion Phase I/IIa study designed to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), and the safety and tolerability profile along with preliminary signs of efficacy of rivoceranib in combination with paclitaxel as a second-line therapy …

adjuvant chemotherapy
platelet count
cancer chemotherapy
fluoropyrimidine
international normalized ratio
  • 3 views
  • 12 Sep, 2021
  • 1 location
Comparing the Quality of Life Between LADG and TLDG for Gastric Cancer_KLASS07 (CKLASS01)).

The present randomized study is designed to compare the quality of life between the patients undergoing laparoscopy-assisted and totally laparoscopic distal gastrectomy for gastric cancer, and

gastric adenocarcinoma
cancer
lymphadenectomy
adenocarcinoma
ct scan
  • 24 views
  • 16 Sep, 2021
  • 1 location
Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis

Background Three-fourths of people diagnosed with gastric cancer will die from it. Researchers want to see if giving cancer drugs in a new way can help people live

human epidermal growth factor
cancer chemotherapy
capecitabine
trastuzumab
endoscopy
  • 101 views
  • 15 Sep, 2021
  • 1 location
Claudin18.2 CAR-T (CT041) in Patients With Gastric or Pancreatic Cancer

A Phase 1b, open label, multi-center, clinical study of Chimeric Antigen Receptor T Cells (CAR-T) targeting claudin18.2 in patients with advanced gastric or pancreatic adenocarcinoma

pancreatic adenocarcinoma
measurable disease
adenocarcinoma
pancreatic cancers
  • 0 views
  • 17 Sep, 2021
  • 5 locations
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

This study will evaluate the efficacy and safety of trastuzumab deruxtecan (T-DXd) compared with ramucirumab and paclitaxel (Ram + PTX) in participants with HER2-positive gastric or gastro-esophageal junction (GEJ) adenocarcinoma who have progressed on or after a trastuzumab-containing regimen and have not received any additional systemic therapy.

  • 1 views
  • 15 Sep, 2021
  • 9 locations
TAS102 in Combination With NAL-IRI in Advanced GI Cancers

This phase I/II trial studies the best dose and how well trifluridine/tipiracil hydrochloride combination agent TAS-102 (TAS-102) and nanoliposomal irinotecan work in treating patients with gastrointestinal cancers that have spread to other places in the body (metastatic) or cannot be removed by surgery. Drugs used in the chemotherapy, such as …

biliary obstruction
obstruction
thromboplastin
serum total bilirubin
glomerular filtration rate
  • 16 views
  • 04 Sep, 2021
  • 3 locations